Close

Repare Therapeutics to Participate in Two Upcoming Investor Conferences Feb 29, 2024 07:05AM
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Feb 28, 2024 07:05AM
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664 Feb 15, 2024 07:05AM
Repare Therapeutics Inc. (RPTX) to Regain Global Rights to Camonsertib Feb 12, 2024 04:07PM
Repare Therapeutics to Regain Global Rights to Camonsertib Feb 12, 2024 04:05PM


Jan 25, 2024 07:02AM Repare Therapeutics Inc. (RPTX) Achieves $40M Roche Clinical Milestone Payment
Jan 25, 2024 07:00AM Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
Jan 8, 2024 07:00AM Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
Jan 4, 2024 04:10PM Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
Jan 4, 2024 04:05PM Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
Nov 15, 2023 07:00AM Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
Nov 9, 2023 07:00AM Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
Nov 7, 2023 07:00AM Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
Nov 6, 2023 07:00AM Repare Therapeutics to Participate in Two Upcoming Investor Conferences
Oct 13, 2023 09:40AM Repare Therapeutics (RPTX) Reports Positive Initial Data from Phase 1 MYTHIC Clinical Trial
Oct 13, 2023 09:40AM Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
Aug 9, 2023 04:05PM Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
Jun 7, 2023 04:05PM Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
Jun 6, 2023 07:00AM Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
May 9, 2023 04:05PM Repare Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
Apr 28, 2023 04:05PM Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
Apr 18, 2023 10:15AM Repare Therapeutics (RPTX) Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors
Apr 18, 2023 10:15AM Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting
Feb 28, 2023 04:05PM Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Jan 19, 2023 07:02AM Repare Therapeutics Inc. (RPTX) Announces $1.5M Payment from Ono Pharmaceuticals
Jan 19, 2023 07:00AM Repare Therapeutics Receives $1.5 Million (¥200 million) Payment from Ono Pharmaceuticals
Nov 9, 2022 04:05PM Repare Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
May 13, 2021 07:00AM Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021
Apr 15, 2021 07:00AM Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors
Feb 26, 2021 07:11AM Cathie Wood's ARK Adds ~1.7M Shares of Twitter (TWTR), Sells Apple (AAPL), Alibaba (BABA)
Feb 24, 2021 06:44AM Cathie Wood's ARK Adds $170M in Tesla (TSLA) Stock on Tuesday's Drop, Among Other Trades
Feb 23, 2021 06:51AM Cathie Wood's ARK Bought Buys ~$200M More Tesla (TSLA) Monday on Sell-Off